Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Eli Lilly and Company (NYSE:LLY) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Eli Lilly and Company (NYSE:LLY) released additional details about the Medicare GLP-1 Bridge program, where it explained how eligible Medicare Part D patients can access its two weight management drugs for a flat $50 per month […]
Our 24/7 Wall St. price target for Eli Lilly (NYSE:LLY) is $1,349.37, pointing to 12.5% upside from a recent price of $1,199.43. We rate LLY a buy with a 90% confidence score. The GLP-1 franchise is compounding faster than the market appreciated last spring, and Foundayo just opened a scalable oral channel to more than ... Eli Lilly Price Prediction: The Case for Double-Digit Upside
If you sort all the top politicians with a portfolio of above $1 million using their annual gains, who do you expect at the top? Likely Nancy Pelosi, but that’s not the case. A Republican Senator named Ashley Moody has gained 310% in the past year using her portfolio. Her portfolio and her (lack of) ... New Nancy Pelosi? Senator Ashley Moody Up 310% in One Year With These Stocks
Eli Lilly and Company (LLY) shares up 18,585% since Big Money bought big in 1990.
U.S. lawmakers have opened a national security probe into Eli Lilly's (NYSE:LLY) clinical trial activities in China. The House Select Committee on China is seeking detailed information on trial oversight, data access, and ties to Chinese institutions. Lawmakers have set a July 17 deadline for Eli Lilly to respond with documents and explanations. Eli Lilly is a major global pharmaceutical company with a large portfolio across diabetes, obesity, oncology, immunology, and other therapeutic...
AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.
Eli Lilly and Altria stand out as defensive stock ideas as investors weigh a hawkish Fed, a pivotal jobs report and shifting market leadership.
Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.
Eli Lilly’s retatrutide has crossed the 30% weight loss benchmark in some patients. Where do GLP-1RAs go from here?
Millions of older Americans are on the cusp of more affordable access to popular weight-loss drugs when a major Medicare coverage expansion kicks in July 1.
Verzenios is a CDK4 and 6 inhibitor that has received approval in China for several indications related to breast cancer.
Medicare is launching a temporary program that will cover Novo’s Wegovy injection and tablets, as well as Lilly’s Zepbound KwikPen formulation and its Foundayo tablets.
Roche won FDA priority review for Enspryng in thyroid eye disease, with a decision date in October and phase III data backing the filing.
Eli Lilly transferred mainland China commercialization rights for Verzenio to Innovent Biologics.
A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country’s military capabilities, according to a...
The abbreviated week in the market could set the tone for the back half of 2026.
Seven pharma companies have been selected for the FDA PreCheck pilot – a framework intended to bolster the US drug supply chain.
LLY is expanding its revenue base beyond Mounjaro and Zepbound with new launches and label expansions that can strengthen long-term growth.
Innovent will take over importing, marketing, and distributing Verzenios in mainland China as generic competition looms
Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines, yet drug development has remained painfully slow, often taking 10 to 15 years while roughly 90% of candidates never reach approval. AI is beginning to change that equation. By ... AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity
Deal gives Innovent commercialization rights in mainland China.
The FDA estimates the PreCheck program could save participating companies up to 14 months by reviewing facilities while they are still under construction
June 30 (Reuters) - A bipartisan group of U. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved in clinical trials conducted in China that helped fuel the communist country's military capability, according to letters seen by Reuters.
SpaceX recently completed a record IPO.
The weight loss tailwind isn't about to come to a halt.
Given its significant hedge fund backing and attractive upside potential, NVIDIA Corporation (NASDAQ:NVDA) is one of the most promising robotics stocks. NVIDIA Corporation (NASDAQ:NVDA) is extending its physical AI ambitions on two fronts simultaneously, pushing deeper into industrial robotics safety while advancing its push into agentic life sciences. On June 23, 2026, NVIDIA Corporation (NASDAQ:NVDA) […]
The latest trading day saw Eli Lilly (LLY) settling at $1, representing a +1.81% change from its previous close.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
